Magnesium supplements treatment with methylphenidate in children with attention-deficit/hyperactivity disorder
Phase 3
- Conditions
- Attention deficit hyperactivity disorder (ADHD).Disturbance of activity and attention
- Registration Number
- IRCT2016062518927N4
- Lead Sponsor
- Vice chancellor for research, Tabriz University of Medical Sciences.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
children between 7-12 aged; ADHD diagnosis by expert pediatric psychology physician using DSM diagnosis index; No prevention for Magnesium supplements; IQ index above 70; Without other psychology disorders; No intake of Magnesium supplements since 2 months ago; Intake of methylphenidate tablet with a dose of 0.5-1 mg/kg/day as a medical treatment. Exclusion criteria:Stop the treatment by the child or parents; incorrect intake of the drug by the child; change the treatment method; Stop the treatment due to the side effects of the drug; Acute physical disease.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in score of Conners' Parent Questionnaire. Timepoint: Beginig of study and 8 weeks later. Method of measurement: Conners' Parent Questionnaire.
- Secondary Outcome Measures
Name Time Method Adverse effects. Timepoint: 8 weeks later. Method of measurement: Patient follow up.